PRL3‐zumab is considered a potential ‘adjuvant immunotherapy’ that can be used after tumour removal surgery to eliminate PRL3+ PGCCs and prevent tumour metastasis and recurrence.182. This evidence concerns the gene PTP4A3 and neoplasm.